Table 3.
Cardiometabolic Outcome Measures in a Study of Pioglitazone-Treated Subjects with Major Depressive Disorder and Abdominal Obesity
| Baseline | Endpoint (Week 12) | Change: Week 12 - Baseline a (N=20) | Endpoint (Week 24) | Change: Week 24 - Baseline a (N=9) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | t | df | p-value | Mean | SD | Mean | SD | t | df | p-value | |
| Anthropometric measurements | ||||||||||||||||
| Systolic blood pressure (mmHg) | 130.5 | 14.6 | 128.9 | 16.5 | −1.6 | 11.9 | −0.604 | 19 | 0.533 | 122.0 | 8.8 | −2.7 | 9.5 | −0.843 | 8 | 0.424 |
| Diastolic blood pressure (mmHg) | 87.8 | 12.1 | 86.2 | 11.4 | −1.6 | 7.5 | −0.921 | 19 | 0.369 | 83.300 | 6.2 | 1.0 | 7.3 | 0.412 | 8 | 0.691 |
| Body mass index (kg/m2) | 40.381 | 7.1 | 40.729 | 7.3 | 0.348 | 1.176 | 1.324 | 19 | 0.201 | 39.536 | 8.6 | 0.519 | 1.928 | 0.807 | 8 | 0.443 |
| Waist circumference (in) | 45.475 | 5.8 | 43.725 | 5.4 | −1.750 | 1.372 | −5.706 | 19 | <0.001 | 42.917 | 6.1 | −2.444 | 1.230 | −5.964 | 8 | <0.001 |
| Weight (lb) | 241.090 | 44.6 | 243.110 | 45.8 | 2.020 | 7.352 | 1.229 | 19 | 0.234 | 228.511 | 45.3 | 2.420 | 12.053 | 0.603 | 8 | 0.563 |
| Glucose metabolism measurements | ||||||||||||||||
| Glucose (mg/dL) | 98.850 | 11.1 | 90.650 | 9.6 | −8.200 | 13.324 | −2.752 | 19 | 0.013 | 92.222 | 15.9 | −4.222 | 9.536 | −1.328 | 8 | 0.221 |
| log(Insulin) | 2.722 | 0.577 | 1.998 | 0.663 | −0.724 | 0.695 | −4.649 | 19 | <0.001 | 1.694 | 0.801 | −0.946 | 0.784 | −3.619 | 8 | 0.007 |
| log(HOMA-IR) | 1.295 | 0.619 | 0.485 | 0.713 | −0.810 | 0.748 | −4.846 | 19 | <0.001 | 0.191 | 0.859 | −0.996 | 0.824 | −3.628 | 8 | 0.007 |
| log(Triglycerides/HDL-C ratio) | 0.633 | 0.741 | 0.289 | 0.517 | −0.344 | 0.664 | −2.315 | 19 | 0.032 | 0.461 | 0.624 | −0.435 | 0.677 | −1.930 | 8 | 0.090 |
| Lipid Panel | ||||||||||||||||
| LDL-cholesterol (mg/dL) | 128.450 | 33.2 | 115.500 | 25.2 | −12.950 | 26.518 | −2.184 | 19 | 0.042 | 121.222 | 21.7 | 4.333 | 43.327 | 0.300 | 8 | 0.772 |
| HDL-cholesterol (mg/dL) | 57.400 | 13.1 | 63.100 | 9.9 | 5.700 | 10.001 | 2.549 | 19 | 0.020 | 61.778 | 10.3 | 11.889 | 6.827 | 5.224 | 8 | <0.001 |
| log(Triglycerides) | 4.656 | 0.630 | 4.423 | 0.485 | −0.233 | 0.564 | −1.852 | 19 | 0.080 | 4.573 | 0.568 | −0.208 | 0.648 | −0.965 | 8 | 0.363 |
| Total cholesterol (mg/dL) | 211.750 | 46.9 | 197.250 | 32.300 | −14.500 | 36.709 | −1.767 | 19 | 0.093 | 204.667 | 29.4 | 7.889 | 63.699 | 0.372 | 8 | 0.720 |
| Inflammatory biomarker measurements | ||||||||||||||||
| log(Highly sensitive C-reactive protein) | 1.990 | 0.779 | 1.118 | 1.031 | −0.872 | 0.724 | −4.346 | 12 | <0.001 | 0.725 | 0.753 | −0.299 | 1.432 | −0.417 | 3 | 0.705 |
| log(Interleukin-1β) | −4.231 | 2.224 | −5.371 | 2.206 | −1.140 | 3.251 | −1.313 | 13 | 0.212 | −4.042 | 1.642 | −0.698 | 0.708 | −2.413 | 5 | 0.061 |
| log(Interleukin-6) | 0.760 | 0.489 | 0.575 | 0.509 | −0.185 | 0.613 | −1.132 | 13 | 0.278 | 0.656 | 0.404 | −0.231 | 0.559 | −1.010 | 5 | 0.359 |
| Tumor necrosis factor-α (pg/ml) | 6.807 | 1.7 | 6.671 | 1.7 | −0.136 | 1.019 | −0.501 | 13 | 0.625 | 7.258 | 1.5 | −0.988 | 1.845 | −1.312 | 5 | 0.246 |
a
Paired t-test
HDL=High density lipoprotein; HOMA-IR=Homeostasis Model Assessment of Insulin Resistance; LDL=Low density lipoprotein